BTLA and B-cell chronic lymphocytic leukemia: Noteworthy, treatment of PBMCs from patients with CLL with anti-BTLA blocking mAb significantly depleted leukemic cell numbers at 48 and 72 h compared with control IgG (Figure 7A).